AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05693662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Session 5
Description: * Breathing break with kindness application,~* The practice of establishing a compassionate relationship with desire,~* Guided meditation to discover the inner pattern practice,~* Kindness meditation: a good friend application,
Study NCT05693662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Session 6
Description: * Pretending practice regarding parents' awareness,~* An expanded version of the practices carried out in previous sessions to raise awareness, the internalizing compassion practice,~* Kindness meditation: a neutral person, kindness towards your body and walking with kindness practices, which are based on mindfulness practices and increase body awareness and mindful movement,
Study NCT05693662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Session 7
Description: * A compassionate letter application, which is carried out by asking parents to think about a situation they have encountered recently or some time ago that still causes distress,~* Kindness meditation: the 'difficult' person, compassion and breathing: yourself and compassionate breathing: others practices,~* Researching how parents can cope with difficulties and implementing a compassionate breath break without words,
Study NCT05693662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Session 8
Description: * Revisiting the good application to enable parents to experience the five senses in a pleasant way,~* Practices of self-forgiveness, asking for forgiveness, forgiving others, gratitude, which can be a way of mending the cracks in parents' relationships with themselves and others,~* Expanding the practice into kindness meditation: groups and all beings,
Study NCT05693662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Session 9
Description: * The practice of allowing parents to choose a day in their lives for a few minutes to pause mindfully,~* A breather for wise and compassionate action practice,~* Calmness meditation application,~* Sharing the joy meditation application,
Study NCT05693662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Session 10
Description: * Evaluating the entire education by telling parents about the practices they can use where help is needed to develop compassion towards self-healing skills,~* River of Life application, which evaluates awareness in depth,~* Saying goodbye.
Study NCT06045637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group included in a psychoeducational program based on the cognitive behavioral approach (experiment)
Description: The 9-session cognitive behavioral approach-based psychoeducation program will last 5 weeks. Sessions; It will be carried out in the form of acquaintance, recognition of trauma and its effects, emotion and thought behavior analysis, cognitive errors, automatic thoughts and alternative thought generation, cognitive emotion regulation strategies, coping with negative emotions, instilling hope and termination session.
Study NCT06536751 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: LED photobiomodulation therapy, once a week, for 08 consecutive weeks in the same day of the institution's standard physiotherapy session that the patient already uses regularly (not linked to the study). PBM will be transcutaneously, punctual application of the LED in the medial and lateral gastrocnemius muscles of the right lower limb, in contact mode, 3J/cm2, with a 850nm wavelenght.
Study NCT06536751 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Institution's Standard Physiotherapy
Description: Physiotherapy treatment on the University, occur 2 therapeutic days per week, for 08 consecutive weeks (one of them in the same day of the PBM session). It consists of the use of motor physiotherapy, posture guidelines, stretching, positioning, joint range gain, ergonomics, sensory stimulation and proprioception, motor strengthening, tonus adjustment, functional training of upper and lower limbs, guidelines for the use of orthoses, stands, parapodium, parallel bars or wheelchair when needed. These are 45-minute sessions conducted by a physiotherapist.
Study NCT06536751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Institution's Standard Physiotherapy
Description: Physiotherapy treatment on the University, occur 2 therapeutic days per week, for 08 consecutive weeks (one of them in the same day of the PBM session). It consists of the use of motor physiotherapy, posture guidelines, stretching, positioning, joint range gain, ergonomics, sensory stimulation and proprioception, motor strengthening, tonus adjustment, functional training of upper and lower limbs, guidelines for the use of orthoses, stands, parapodium, parallel bars or wheelchair when needed. These are 45-minute sessions conducted by a physiotherapist.
Study NCT06536751 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation Placebo
Description: The same procedures of PBM group but device will be turned off
Study NCT05119855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV Vaccine
Description: 9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular (IM) injection
Study NCT05119855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273 Vaccine
Description: mRNA-1273 50 mcg dose administered as a 0.25-mL IM injection
Study NCT04857398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin icodec
Description: Participants will get insulin icodec once a week for 6 weeks. The medicine will be injected under the skin.~The study will last for 15 to 22 weeks.
Study NCT05263635 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Enhanced Recovery After Surgery (ERAS)
Description: Patients will receive the standard of care treatment for surgery and post-operative pain management, following the Enhanced Recovery After Surgery (ERAS) protocol
Study NCT06043804 — intervention group
Intervention type: OTHER
Intervention: Doppler ultrasound measurement of changes in uterine artery blood flow
Description: Doppler ultrasound measurement of changes in uterine artery blood flow
Study NCT04746976 — intervention group
Intervention type: DRUG
Intervention: Diroximel Fumarate
Description: As described in the arm.
Study NCT05421845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile-based combining with hospital-based lifestyle interventions
Description: The same as that stated in arm descriptions.
Study NCT05580679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: Application time of the massage: 30 minutes after meals, twice a day, at 10:00 in the morning and at 16:00 in the evening.~Application time of the massage: 15 minutes each Materials needed: Gloves, Liquid Vaseline, Paper Towel Massage methods used: Efflorage, Petrissage, Vibration
Study NCT04981392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary care text message outreach to unvaccinated patients and resources to support PCPs
Description: Patients: Eligible patients will receive a series of text messages from their PCP or primary care clinic recommending a study website as a trusted source of information about the COVID-19 vaccines and information on how and where to schedule a vaccination.~Providers: PCPs will receive resources to support their conversations with patients about the COVID-19 vaccines (factsheets, prescription pads, electronic smartphrase).
Study NCT04856891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8.
Study NCT04856891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05082831 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: microfracture surgery + HST003
Description: This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery. The primary purpose of the study is to compare the two groups: microfracture surgery + HST003 as compared to the microfracture surgery only group.
Study NCT05497635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1002 Injection
Description: Intravenous injection
Study NCT05497635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection
Study NCT04723758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GI Genius-assisted diagnostic colonoscopy
Description: Participants will undergo diagnostic colonoscopy, which will be identical to the normal standard of care at the unit where they are undergoing their procedure, except that GI Genius will be turned on during the procedure.
Study NCT04723758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Colonoscopy
Description: Diagnostic colonoscopy will be performed as per the standard of care for the unit where the patient is having their procedure.
Study NCT05751642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALXN1920
Description: Participants will receive a single dose of ALXN1920 by Subcutaneous (SC) injection.
Study NCT05751642 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single dose of Placebo by SC injection, SC infusion or IV infusion.
Study NCT05751642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALXN1920
Description: Participants will receive a single dose of ALXN1920 by SC infusion.
Study NCT05751642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALXN1920
Description: Participants will receive a single dose of ALXN1920 by Intravenous (IV) infusion.
Study NCT05360368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: A Recombinant Humanized Anti-EGFR Monoclonal Antibody, HLX07 will be administered as a single intravenous (IV) infusion on Day 1 in each 3-week cycle
Study NCT04896255 — intervention group
Intervention type: DRUG
Intervention: peginterferon alpha based regimen
Description: peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
Study NCT04896255 — intervention group
Intervention type: DRUG
Intervention: nucleos(t)ide
Description: peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
Study NCT06193330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antibiotic-coated plate
Description: A plate for fixing long bone fractures is coated with antibiotics cement prepared in theatre
Study NCT06193330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external fixator
Description: external fixators are applied to participants with severe long bone fractures
Study NCT05543395 — intervention group
Intervention type: BEHAVIORAL
Intervention: Domestic Violence Questionnaire
Description: Domestic Violence Questionnaire
Study NCT05483608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vertical climbing ergometer exercise
Description: Exercise using the CLMBR, a vertical climbing exercise ergometer.
Study NCT05483608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recumbent cycling
Description: Exercise using a recumbent cycle ergometer
Study NCT05105152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC-DARIC33
Description: Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration
Study NCT05027971 — intervention group
Intervention type: DEVICE
Intervention: Flexiva Pulse High Power Single-Use Laser Fibers
Description: Flexiva Pulse High Power Single-Use Laser Fibers are intended to be used as a device that transmits Ho:YAG laser energy from cleared laser consoles to urological anatomy.
Study NCT06576596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apnoeic Oxygenation
Description: One approach to preventing adverse respiratory events due to hypoxaemia during paediatric anaesthesia is the use of apnoeic oxygenation. The principle is to deliver oxygen to the airways of anaesthetised patients via a conventional nasal cannula. As less carbon dioxide is produced than oxygen is consumed during apnoea, the supply of oxygen to the upper airways leads to an 'inward diffusion' of oxygen, which may prolongs the time until desaturation and hypoxaemia occur.
Study NCT06435299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis oil
Description: Patients in this arm will have to take Cannabis oil (50mg/mL) twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
Study NCT06435299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this arm will have to take Placebo oil twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
Study NCT06032234 — intervention group
Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study
Study NCT04872959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealthReveal
Description: In the Intervention arm, for each study visit, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' EHR.~The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.~Additionally, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed.~In the Usual Care arm, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed.
Study NCT04981457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol and iso sorbide mononitrates
Description: drug
Study NCT05289557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bonjesta
Description: Extended-release tablets contain 20 mg of doxylamine succinate and 20 mg of pyridoxine hydrochloride. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
Study NCT05289557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pills with no active ingredients. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
Study NCT05406726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: palmitoylethanolamide
Description: palmitoylethanolamide is an lipid based endocannabinoid naturally made by the body and is present in several common foods such as eggs
Study NCT05406726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a capsule filled only with maltodextrin will be used as a placebo
Study NCT04960618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive gemcitabine 1000 mg/m2 on days 1 and 8 on 21-days cycles for up to 6 cycles
Study NCT04960618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be introduced with cycle 2 and will be given on day 1 of each 21-day cycle for up to 35 cycles
Study NCT06522867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraocular pressure measure
Description: The intraocular pressure of the subjects using either the Goldmann applanation tonometer, Icare or Accupen. The order of the measure is randomized.
Study NCT04887285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Subjects in the virtual reality group will be offered a variety of immersive environments to choose from (mountains, beach, rainforest and temperate forest) in addition to local anesthetic.
Study NCT04887285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous sedation
Description: Sedation will be administered using low-dose midazolam and/ or fentanyl. We will use a wide range of dosing (1-5 mg for midazolam, up to 150 mcg for fentanyl) to maximize generalizability and account for widespread variability in clinical circumstances, medical practice and patient response (personalized medicine). Sedation will be titrated to effect by a board-certified or eligible anesthesiologist so that patients remain responsive to verbal stimuli.
Study NCT04887285 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Patients will receive superficial local anesthetic with 1% lidocaine. Local anesthetic will be administered by the physician performing the procedure titrated to patient comfort.
Study NCT04903002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 24-IU oxytocin
Description: Patients will self-administer a 2-week course of 24-IU intranasal oxytocin \[4-IU per puff (12-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).
Study NCT05771792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECCENTRIC EXERCISE
Description: Eccentric Exercise training group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, Eccentric Exercise training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. Eccentric exercise training protocol is as follow: Prone Hamstring Curl, Seated TheraBand Hamstring Curl, Exercise Ball (or glider) Bridge with Curl, Stiff-Legged Deadlift, Single Leg Deadlift, Nordic Hamstring Curl.
Study NCT04903002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 48-IU oxytocin
Description: Patients will self-administer a 2-week course of 48-IU intranasal oxytocin \[4-IU per puff (24-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).
Study NCT04903002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Patients will receive an intranasal placebo containing the same ingredients as the oxytocin nasal spray with the exception of active oxytocin. Administration schedule and procedure will be identical to that described in 24-IU oxytocin.
Study NCT04269070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standing condition
Description: Participants will be asked to stand an additional 6 minutes per hour above their median standing time from the observed time in the usual behavior condition.
Study NCT05771792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL EXERCISES PROGRAM
Description: The participant of the Control Group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, conventional training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. The exercise will be as follow: Side Lunges, Split Squats, Calf Raises.
Study NCT05298306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAT8881
Description: In Part A, LAT8881 will be given as a single intravenous infusion at doses of 0.8, 1.2 and 1.8 mg/kg.~In Part B, a single intravenous infusion of LAT8881 will be given, the dose to be determined by the results in Part A
Study NCT05298306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo'given as a single intravenous infusion at all dose levels
Study NCT06323707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Eight sessions of moderate intensity aerobic exercise using recumbent bike within the cancer institution.
Study NCT06323707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management e-module
Description: Eight 15 minute self-management e-modules related to exercise and physical activity for cancer survivors.
Study NCT04964024 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 antibodies
Description: Analysis of the results of the serological response to COVID-19 and/or Vaccine
Study NCT06259955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: In the hybrid education process, the group that received their first year education online realized their first face-to-face clinical practice this year. In the fall semester, internal medicine nursing course and practice, and in the spring semester, surgical diseases nursing course and practice. These two practice areas, which have a high tendency to make medical errors, require clinical decision-making skills and increase stress levels, constitute the beginning of clinical practice. Studies show that the most stressful period for students is the second year of their education (Alzayyat \& Al- Gamal, 2014; White, 2011; Coram, 2015). This is because their professional knowledge and skills are not yet fully developed and they are not sufficiently prepared to meet the demands for higher level knowledge and skills (Alzayyat \& Al- Gamal, 2014; Coram, 2015). Based on the results of these studies, our study group consisted of second-year students.
Study NCT05116358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy device
Description: The active phototherapy device will emit light